Anavex Life Sciences reported preliminary results for the fiscal second quarter ended March 31, 2026, posting a net loss of $5.3 million, or $0.06 per share, compared with a $11.2 million loss in the year-ago quarter. Cash and cash equivalents were $127.4 million as of March 31, 2026, and the company expects this balance to fund operations into mid-to-late fiscal 2028. Management said it is prioritizing engagement with the U.S. FDA around a data-driven regulatory strategy for its lead candidate blarcamesine across early Alzheimer’s disease, Rett syndrome and Fragile X syndrome.

Financial Highlights

  • Preliminary net loss for the three months ended March 31, 2026: $5.3 million (basic and diluted loss per share: $0.06).
  • Preliminary net loss for the six months ended March 31, 2026: $11.0 million (basic and diluted loss per share: $0.12).
  • Preliminary cash and cash equivalents as of March 31, 2026: $127.4 million (up from $102.6 million as of September 30, 2025).
  • Preliminary total operating expenses for the quarter: $6.5 million (general and administrative $2.3 million; research and development $4.2 million).
  • Preliminary total assets as of March 31, 2026: $128.8 million; total liabilities: $7.1 million; total stockholders’ equity: $121.7 million.

Business Highlights

  • Regulatory strategy: Opened an IND application for early Alzheimer’s disease in the U.S. at the end of March 2026 to enable U.S. clinical studies and FDA engagement on the development path for blarcamesine.
  • Clinical pharmacology work: Two foundational studies under the IND are proceeding in the U.S.—an ADME study (anticipated initiation in Q3 2026) and a drug-drug interaction (DDI) study with dosing already underway.
  • Rett syndrome program: FDA has granted Orphan Drug, Rare Pediatric Disease and Fast Track designations; a Phase 3 protocol for adults is aligned with the FDA and the company plans to discuss adding pediatric patients.
  • Fragile X program: FDA has granted Orphan Drug designation; the company plans to initiate discussions with the FDA on clinical development strategy building on that designation.
  • Corporate actions: Submitted a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1) on July 20, 2026, and participated in AAIC 2026 to engage with the Alzheimer’s research and clinical community.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.